Expired

Although this activity is no longer certified for credit, we believe that it contains important information and hope you'll review, print or email it to a colleague.

Activity:

Immunotherapy of Melanoma Using Checkpoint Blockade

CME Course Duration:

Start Date: 01-28-2010
End Date: 01-27-2011

Speaker: Jedd D. Wolchok, MD, PhD Associate Attending Memorial Sloan-Kettering Cancer Center New York, New York

Featured Topic Information: Please click here to view a webcast (registration required) Please click here to view the slide library (registration required) Please click here to listen to the audio (registration required) Please click here to take the post test and evaluation (registration required) Please click here if you have any comments or questions relating to this topic

Target Audience

This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who screen for and/or treat melanoma.

Educational Objective

• Analyze the role that CTLA-4 inhibition plays in promoting antitumor immune responses
• Describe different patterns of clinical response to ipilimumab

Faculty Disclosure Statement

Dr. Jedd D. Wolchok, has disclosed he serves as a consultant to Bristol Myers Squibb, Novartis, and Schering-Plough Corporation.

This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Paradigm Medical Communications, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.

Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.